In conclusion, our results suggested that genetic polymorphisms of the lncRNA-p53 regulatory network could play a potential role in reducing treatment-related toxicities and improving outcomes for NPC patients. This evidence concerns the gene TP53 and nasopharyngeal carcinoma.